Pallas Capital Advisors’s Vanda Pharmaceuticals VNDA Stock Holding History

Pallas Capital Advisors’s Portfolio VNDA Stock Details VNDA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$114K	Buy	+18,605	New	+$122K	﹤0.01%	942

Other funds holding VNDA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

ACM

AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Pallas Capital Advisors's VNDA Position: Q2 2026 in Review

Pallas Capital Advisors opened a new position in Vanda Pharmaceuticals (VNDA) in Q2 2026: 18,605 shares worth $114K. The stake represents ﹤0.01% of the portfolio and ranks #942 among its holdings.

172 funds tracked by Wall St. Rank hold VNDA as of Q2 2026.

Pallas Capital Advisors held 18,605 shares of Vanda Pharmaceuticals worth $114K as of Q2 2026.
Vanda Pharmaceuticals was a new Pallas Capital Advisors position in Q2 2026.
Vanda Pharmaceuticals made up ﹤0.01% of Pallas Capital Advisors's portfolio in Q2 2026, its #942 holding.
172 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q2 2026.

Based on Pallas Capital Advisors's 13F filing for Q2 2026, filed 7 Aug 2026.